Spots Global Cancer Trial Database for Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane
Official Title: Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane
Study ID: NCT00291798
Conditions
Interventions
Study Description
Brief Summary: The objective of the present clinical investigation is to determine whether hormonal therapy given preoperatively is able to reduce tumor size to an extent that facilitates breast-conserving procedures.
Detailed Description: This open, prospective multicenter Phase II pilot trial investigates the efficacy of exemestane, 25 mg once daily over 4 months, in postmenopausal women with primary breast cancer, measured in terms of clinical response
Eligibility
Minimum Age: 59 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Hospital of Guessing, Guessing, Burgenland, Austria
State Hospital Klagenfurt, Surgery, Klagenfurt, Carinthia, Austria
State Hospital Wolfsberg, Wolfsberg, Carinthia, Austria
Hospital of Wiener Neustadt, Wiener Neustadt, Lower Austria, Austria
Gynaegological Medical University of Graz, Graz, Styria, Austria
Medical University of Graz, Oncology, Graz, Styria, Austria
Hospital BHS Linz, Linz, Upper Austria, Austria
General Hospital Linz, Linz, Upper Austria, Austria
Paracelsus Medical University Salzburg, Oncology, Salzburg, , Austria
Medical University of Vienna, General Hospital, Vienna, , Austria
Hanusch Hospital, Vienna, , Austria
Contact Details
Name: Brigitte Mlineritsch, MD
Affiliation: Austrian Breast & Colorectal Cancer Study Group
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
